Condensed ring compound
CA 2527691 C · Owner: Negoro, Nobuyuki · Inventors: Yasuma, Tsuneo; Fukatsu, Kohji; Negoro, Nobuyuki
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention aims at providing a novel fused ring compound having a GPR40 receptor function modulating action and being useful as an insulin secretagogue or a pharmaceutical agent for the prophylaxis or treatment of diabetes more , particularly, a compound represented by the formula: (see formula I), wherein Ar is an optionally substituted cyclic group ring A is a ring optionally further substituted (provided that the ring is not thiazole, oxazole, imidazole and pyrazole) Xa and Xb are each independently a bond or a spacer having a main chain of 1 to 5 atom(s), Xc is O, S SO or SO2, (see formula II) is, (see formula III) (see formula IV), (see formula V) or (see formula VI) …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 28, 2004 and granted January 22, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 28, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 28, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.